A team of researchers, led by Dr Raphaelle Pezzani, University of Padova, conducted a trial comparing different OSA-stabilized commercial dietary supplements in order to define their bioaccessibility, bioavailability and safety in a model of human intestinal epithelium and biocompatibility within glycocalyx.
